103 results about "Luciferase" patented technology

A modified beetle luciferase protein which is an environmentally sensitive reporter protein is provided.

The invention discloses a luciferase complementary quantum dot biosensor as well as a construction method and application thereof, belonging to the technical field of biosensing. The luciferase complementary quantum dot biosensor comprises a quantum dot, a luciferase amino terminal fragment, a luciferase carboxyl terminal fragment, a probe of specifically recognizable determinand and a substrate which have bioluminescence reaction with luciferase. With the combination of optical advantages of the quantum dot sensor, a catalysis function can be reconstructed through induction complementation of the luciferase amino terminal fragment and the luciferase carboxyl terminal fragment on the surface of the quantum dot, a novel high-sensitivity biosensor can be constructed, and the biosensor is low in background noise, high in sensitivity, stable in structure and easy to use, can be used in high-target detection on multiple biological markers, and is applicable to accurate quantification on target testing articles in homogeneous systems.

The invention relates to a plasmid vector. According to the plasmid vector, a 3'UTR (untranslated regions) sequence of an ABCB1 gene is inserted into the 6832-7349 bp segment of pmirGLODual-Luciferase-promoter plasmid vector. The invention also relates to a host cell containing the plasmid vector, a construction method of the plasmid vector and use of the plasmid vector in selection of relative microRNA (ribonucleic acid) of multi-drug resistance. The invention provides a fast, efficient, simple and practicable method for accurately forecasting microRNA which regulates human ABCB1 gene expression so that a new way for improving the sensitivity and specificity of microRNA detection, researching, developing and detecting drugs for reversing multi-drug resistance by virtue of gene regulation is opened.

The invention provides a kit and method for detecting an autoimmune antibody of the type-I diabetes mellitus and belongs to the technical field of biochemical medicine detection. The method comprises the following steps of: adding a luciferase as an antibody fusion protein, wherein the luciferase as the antibody fusion protein is generated by 293 cell culture and can be specifically combined with a diabetes mellitus autoantibody in serum of a patient; then, adding protein-A agarose, depositing a fusion protein as an antibody compound, centrifuging, and then, absorbing the uncombined fusion protein from a supernatant liquid; and then, adding a luciferase substrate, and detecting the fluorescence intensity by using a fluorescence detection instrument to finally measure the content of the diabetes mellitus autoantibody in a sample to be detected. Compared with the traditional HPLC (High Performance Liquid Chromatography), a micro-quantitative fluorescence detection instrument used for detecting in the method has the advantages of simplicity in operation, no need of uncovering to block a pollution way, high sensitivity and signal to noise ratio, stable and reliable measured value and capability of ensuring reliable experiment result and safety of operating personnel and meeting the requirements of micro quantity and regent saving.

The invention relates to the field of biological medicine, in particular to recombinant plasmid for screening an Nrf2 activating agent and a construction method and application thereof. The recombinant plasmid comprises one or two or above series antioxidant reaction elements, basal transcription elements, secretion-type luciferase genes and secretion-type alkaline phosphatase genes. Compared with the prior art, as secretion-type luciferase is used as reporter genes, the detection sensitivity is high, cells do not need to be pyrolysed when the activity of the luciferase genes is detected, high-throughput screening and comparing and detection of the long-term effect of an antioxidant are achieved, and an efficient, rapid, simple and convenient method is provided for screening the antioxidant or detecting the activity of the antioxidant, and the recombinant plasmid can be applied to screening of natural medicine with the antioxidation effect and artificially-synthesized compounds.

Provided is a method of detecting infection in a wound caused by an infecting organism at a wound site. Also provided is a system for detecting an infection in a wound at a wound site. Additionally, a porous pad comprising luciferase is provided.

The invention provides a novel biological activity determination method of exendin-4-HAS Byetalog. The basic principle of the method is that a GLP-1R (Glucagon-Like Peptide-1R) and a cAMP (cyclic Adenosine Monophosphate) response element (CER) report gene carrier are used for co-transfection of a CHO-K1 cell, and the steps of pressurization, sieving and monoclonal separation and cultivation are carried out to obtain a stable monoclonal cell strain CHOglplr/crec14. After the GLP-1R is combined with a ligand, a series of signal transduction is carried out to stimulate the expression of CRE reporter gene luciferase, and the activity of the Byetalog is quantified by detecting the change of the expression of the luciferase after the Byetalog stimulates. The specific detection steps are as follows: 6000 CHOglplr/crec14 cells are placed on each pore of a 96-pore plate to be cultured for 16-18 hours; the Byetalog with different concentrations is added to stimulate the cells for 6 hours; the activity of the luciferase is detected. The method is simple to operate, sensitive in reaction and small in variability, and has very important meaning to quality control and clinical application of the Byetalog.

The invention discloses a pseudovirus of COVID-19 coronavirus as well as a preparation method and application of the pseudovirus, and belongs to the technical field of biological medicines. Accordingto the pseudovirus, COVID-19 membrane protein participates in packaging of a defective virus genome with a reporter gene, one or more sections of exogenous sequences for encoding bioactive substancescan be included under the condition that the reporter gene sequence is carried or not carried, the reporter gene is selected from enhanced green fluorescent protein (EGFP) or luciferase. the defectivevirus genome or a portion thereof are derived from VSV, HIV, SARS and other viruses, and one or more structural genes contained in the defective virus genome can be removed or regulated to be inactivated. The pseudovirus can reduce the risk of virus research to the maximum extent, and can also be used for screening antiviral drugs, determining the titer of a neutralizing antibody in the body of an infected person, searching for an epitope combined with the neutralizing antibody on a COVID-19 coronavirus surface antigen and evaluating the immune effect of vaccines.

The invention discloses application of a 4N heterocyclic compound as an inhibitor for Th17 cell differentiation. In virtue of a luciferase activity screening system based on the activity of transcription factors, it is found that the 4N heterocyclic compound with a general formula as described in the specification has capability in inhibiting the key transcription factor ROR gamma t of Th17 cell differentiation and the inhibition capability EC50 is in a range of 0.2 to 1.5 [mu]M. In-vitro Th17 cell differentiation experiments prove that the 4N heterocyclic compound is capable of inhibiting Th17 differentiation, including substantially reducing the transcription expression of ROR gamma t, inhibiting the transcription expression of the effector molecules IL17A and IL17F of Th17 and obviously inhibiting the secretion level of IL17A cytokines in a culture. The 4N heterocyclic compound is expected to be developed into a drug used for treating autoimmune diseases, especially psoriasis, systematic lupus erythematosus, multiple sclerosis, rheumatoid arthritis, asthma or inflammatory intestinal diseases.

The invention discloses a naphthenic-base mono substituted amino fluorescein compound as well as a preparation method and application thereof. The naphthenic-base mono substituted amino fluorescein compound has a structural general formula (described in the specification) or a free form thereof, wherein n is 0-9, and m is 1-9; when n is equal to m, R is mono substituted groups such as a hydrogen group, methyl, ethyl, propyl and halogen; and when n is not equal to m, R is the hydrogen group. The naphthenic-base mono substituted amino fluorescein compound can be used for detecting distribution and imaging of luciferase in vitro, cells and vivo by detecting the presence and quantity (including enzyme level, cellular level and animal level) of the luciferase by virtue of bioluminescence, can be also used for detecting distribution and imaging of ATP in vitro, cells and vivo by detecting the presence and quantity (including enzyme level, cellular level and animal level) of ATP and can be used for detecting pharmacological action of a medicine in enzyme level, cellular level and animal level as a report signal in the presence of luciferase, ATP and Mg<2+>.

The invention discloses a molecular probe for detecting malonyl coenzyme A. The moklecular probe contains fusion protein of NanoLuc luciferase large subunit, FapRdelta43 protein and NanoLuc luciferasesubunit from the N end to the C end. The molecular probe can both detect the malonyl coenzyme A in the extract of sample in vitro and detect and perform detection and dynamic observation on the malonyl coenzyme A in living cells; most importantly, the malonyl coenzyme A can be detected in different organelles of the living cells, simpleness in operation is achieved, and therefore, the fusion protein has the potential to become a commercial product.

The present invention includes a luciferase-based high-throughput screening assay that identifies compounds that are inhibitors of cellular metabolism. This assay is applicable to all bacterial and eukaryotic membranes.

The invention discloses a method for constructing a genetic engineering cell strain of an obesity-resistant medicine target point UCP1, and besides, discloses establishing and application of an obesity-resistant medicine high-flux screening model. Mainly a CRISPR/Cas9 system is related and utilized, two unique sgRNAs are designed, luciferase-T2A-tdTomato-WPRE-pA is knocked in after N end ATG of aUCP1 gene of cells, particularly luciferase and tdTomato are knocked in gene sites of immortalization brown fat cells UCP1, a first stably-transfected brown fat cell strain in which luciferase and tdTomato are inserted in a promoter region of the UCP1 is formed, and the first stably-transfected brown fat cell strain is applied to high-flux screening of obesity-resistant medicines, evaluation of the obesity-resistant medicines, evaluation of obesity-resistant active substances of organisms and development of a UCP1 detection reagent kit. The UCP1 is uncoupling protein specifically expressed atbrown fat tissue, and is an obesity-resistant new target point. The construction of the stably-transfected genetic engineering cell strain has important significance in the aspects of applying reportgenes and a high-connotation method, performing high-flux screening on a compound library acutely, accurately and efficiently, and obtaining obesity-resistant medicines capable of promoting thermogenesis and reducing weight.